CJ HealthCare, launches Korea’s 30th novel drug K-CAB Tab.
Feb. 27, 2019
This content is a news material distributed on February 27, 2019, and the current content may differ, so please consider it.
CJ HealthCare, launches Korea’s 30th novel drug K-CAB Tab.
- K-CAB Tab., a new drug for GERD, launched on March 1 with insurance coverage
- “P-CAB of KOREA,” which overcomes the limitations of existing treatments with features and strong points such as fast drug efficacy and suppression of gastric acid secretion at night
- K-CAB tab., The first p-cab class drug in the world to obtain an indication for both ERD and NERD
- Expected to replace the paradigm for the treatment of GERD in a total of 20 countries including Korea, China, Vietnam, and 17 countries of Central and South America
photo. CJ HealthCare K-CAB Tab.
CJ HealthCare's K-CAB Tab., a new drug for GERD and Korea’s 30th novel drug, entered the GERD market in earnest.
According to the notice of the Ministry of Health and Welfare, K-CAB Tab. will receive insurance benefits for use in the treatment of ERD and NERD on the first day of next month.
K-CAB Tab. is a treatment for GERD on the P-CAB (Potassium Competitive Acid Blocker) drug known as the next generation class.
In July of last year, K-Cab became the first P-CAB drug in the world to obtain an indication for both ERD and NERD.
K-CAB Tab., meaning 'Korea's new P-CAB drug', features 'fast action, 'maximum gastric acid secretion suppression effect from the first day of use', and 'night gastric acid secretion suppression effect'. It is expected to replace the market for the treatment of GERD in the future that overcomes the limitations of PPI class drugs.
In the case of taking 1 tablet of K-CAB once a day, the drug showed efficacy in 1 hour. The pH level was maintained at 4 or higher even at night, and the effect of suppressing gastric acid secretion at night was confirmed.
In addition, K-CAB Tab. demonstrated the maximum gastric acid secretion inhibitory effect from the first day as the time when the pH in the stomach was maintained above 4 on the first day was similar to the 14th day.
It is also characterized by increased convenience of taking compared to conventional PPI class drugs, as it shows similar efficacy at any time, regardless of before or after a meal.
In 2015, CJ HealthCare inked a $95.3 million licensing-out deal with China’s Luoxin
and announced the excellence of domestic new drugs on the global stage.
In 2018, it also agreed to license out the drug to Vietnam’s Vimedimex Medi Pharma.
In February, it signed an $84 million worth deal with Mexico-based Laboratorios Carnot to supply the drug for 10 years.
Kang Seok-Hee, CEO of CJ Healthcare, said, “As K-POP and K-FOOD all over the world brought a new fashion, “P-CAB of KOREA” K-CAB will focus on improving the quality of life of patients by rapidly changing generations in the market for the treatment of GERD.”
K-CAB tab. was released in one dose of 50mg, and was priced at 1,300 won per tablet.
Prior to the launch, CJ HealthCare signed a domestic co-promotion contract with Chong Kun Dang in last January. The company held a launching symposium for more than 800 medical staff nationwide and received enthusiastic attention.